While the need for trastuzumab-based adjuvant chemotherapy may be disputed in pT1a-b HR-positive/Her2-positive tumors (30, 87), chemotherapy is rarely omitted in node-negative TN BC larger than 5 mm. This evidence concerns the gene ERBB2 and breast cancer.